Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III Clinical Trial

Rahimi et al., Jundishapur Journal of Natural Pharmaceutical Products, doi:10.5812/jjnpp-129817
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 33% Improvement Relative Risk Hospitalization time 8% N-acetylcysteine  Rahimi et al.  ICU PATIENTS  RCT Is very late treatment with N-acetylcysteine beneficial for COVID-19? RCT 40 patients in Iran Lower mortality with N-acetylcysteine (not stat. sig., p=0.19) c19early.org Rahimi et al., Jundishapur J. Natural .., Oct 2022 FavorsN-acetylcysteine Favorscontrol 0 0.5 1 1.5 2+
14th treatment shown to reduce risk in February 2021
 
*, now with p = 0.000027 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
RCT 40 ICU patients in Iran, showing lower mortality with NAC treatment, without statistical significance. Single dose intravenous NAC 300 mg/kg.
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 31% lower mortality [14‑44%] from meta analysis of the 20 mortality results to date.
risk of death, 33.3% lower, RR 0.67, p = 0.19, treatment 10 of 20 (50.0%), control 15 of 20 (75.0%), NNT 4.0.
hospitalization time, 7.5% lower, relative time 0.92, p = 0.63, treatment 20, control 20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rahimi et al., 8 Oct 2022, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 10 authors.
This PaperN-acetylcys..All
{ 'indexed': {'date-parts': [[2024, 1, 4]], 'date-time': '2024-01-04T20:59:31Z', 'timestamp': 1704401971080}, 'reference-count': 30, 'publisher': 'Briefland', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2013, 1, 1]], 'date-time': '2013-01-01T00:00:00Z', 'timestamp': 1356998400000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': ['brieflands.com'], 'crossmark-restriction': False}, 'abstract': '<jats:p>Background: Today, various drugs have been investigated as the primary or ' 'complementary treatment for coronavirus disease 2019 (COVID-19). N-acetylcysteine (NAC) has ' 'been used as a mucolytic in pulmonary diseases. This drug apparently contributes to the ' 'retrieval of the intracellular antioxidant system. Objectives: This study aimed to determine ' 'the efficacy of NAC in severe COVID-19 patients admitted to the intensive care unit (ICU). ' 'Methods: This single-blinded randomized controlled phase III clinical trial included 40 ' 'patients with confirmed COVID-19 (based on polymerase chain reaction) admitted to the Shahid ' 'Mohammadi Hospital’s ICU, Bandar Abbas, Iran, in 2020. All cases had severe COVID-19. They ' 'were allocated randomly to two equal groups. Patients in the control group received standard ' 'drug therapy based on the treatment protocol of the national COVID-19 committee, while those ' 'in the NAC group received a single dose of intravenous NAC (300 mg/kg) upon admission to the ' 'ICU in addition to standard drug treatment. Clinical status and laboratory tests were done on ' 'admission to the ICU and then 14 days later or at discharge without knowing the patient ' 'grouping. Results: The two groups were comparable regarding age, gender, and other baseline ' 'laboratory and clinical parameters. At the final evaluation, respiratory rate (21.25 ± 4.67 ' 'vs. 27.37 ± 6.99 /min) and D-dimer (186.37 ± 410.23 vs. 1339.04 ± 2183.87 ng/mL) were ' 'significantly lower in the NAC group (P = 0.004 and P = 0.030, respectively). Also, a lower ' 'percentage of patients in the NAC group had lactate dehydrogenase (LDH) ≤ 245 U/L (0% vs. ' '25%, P = 0.047). Although the length of ward and ICU stay was shorter in the NAC group than ' 'in controls, the difference was statistically insignificant (P = 0.598 and P = 0.629, ' 'respectively). Mortality, on the other hand, was 75% in the control group and 50% in the NAC ' 'group, with no statistically significant difference (P = 0.102). Concerning the change in the ' 'study parameters, only the decrease in diastolic blood pressure (DBP) was significantly ' 'higher with NAC (P = 0.042). The intubation and mechanical ventilation rates were higher, ' 'while oxygen with mask and nasal oxygen rates were lower with NAC, but the difference was ' 'statistically insignificant. Conclusions: Based on the current research, NAC is related to a ' 'significant decrease in RR, D-dimer, and DBP in severe COVID-19. Also, LDH was significantly ' 'lower in the NAC group than in the controls. More research with larger sample sizes is needed ' 'to validate the current study results.</jats:p>', 'DOI': '10.5812/jjnpp-129817', 'type': 'journal-article', 'created': {'date-parts': [[2023, 3, 19]], 'date-time': '2023-03-19T15:19:21Z', 'timestamp': 1679239161000}, 'update-policy': 'http://dx.doi.org/10.5812/crossmark_update_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients: A Randomized Controlled Phase III ' 'Clinical Trial', 'prefix': '10.5812', 'volume': '18', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-4313-7352', 'authenticated-orcid': False, 'given': 'Arash', 'family': 'Rahimi', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6636-198X', 'authenticated-orcid': False, 'given': 'HamidReza', 'family': 'Samimagham', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ladan', 'family': 'Hajiabdolrrasouli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehdi', 'family': 'Hassani Azad', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2345-8642', 'authenticated-orcid': False, 'given': 'Ali', 'family': 'Salimi Asl', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatemeh', 'family': 'Khajavi Mayvan', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8520-2709', 'authenticated-orcid': False, 'given': 'Elham', 'family': 'Boushehri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohsen', 'family': 'Arabi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sepideh', 'family': 'Pazhoohesh', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9127-3594', 'authenticated-orcid': False, 'given': 'Mitra', 'family': 'Kazemi Jahromi', 'sequence': 'additional', 'affiliation': []}], 'member': '3819', 'published-online': {'date-parts': [[2023, 1, 13]]}, 'reference': [ { 'key': 'key-A129817REF1-1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.6775'}, {'key': 'key-A129817REF2-2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1985'}, { 'key': 'key-A129817REF3-3', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.5394'}, { 'key': 'key-A129817REF4-4', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41577-020-0311-8'}, { 'key': 'key-A129817REF5-5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052'}, {'key': 'key-A129817REF6-6', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/CS20200363'}, { 'key': 'key-A129817REF7-7', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054-020-03015-0'}, {'key': 'key-A129817REF8-8', 'doi-asserted-by': 'publisher', 'DOI': '10.34172/ddj.2021.18'}, {'key': 'key-A129817REF9-9', 'doi-asserted-by': 'publisher', 'DOI': '10.5812/semj.110656'}, { 'key': 'key-A129817REF10-10', 'doi-asserted-by': 'publisher', 'DOI': '10.5812/archcid.106847'}, { 'key': 'key-A129817REF11-11', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.8707'}, { 'key': 'key-A129817REF12-12', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0076-6879(02)52039-5'}, { 'key': 'key-A129817REF13-13', 'doi-asserted-by': 'publisher', 'DOI': '10.1089/ars.2012.4604'}, { 'key': 'key-A129817REF14-14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbamcr.2016.09.012'}, { 'key': 'key-A129817REF15-15', 'doi-asserted-by': 'publisher', 'DOI': '10.1164/rccm.201802-0245OC'}, { 'key': 'key-A129817REF16-16', 'doi-asserted-by': 'publisher', 'DOI': '10.1053/j.gastro.2009.06.006'}, { 'key': 'key-A129817REF17-17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/bs.apha.2018.12.004'}, { 'key': 'key-A129817REF18-18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tips.2019.04.015'}, { 'key': 'key-A129817REF19-19', 'author': 'Ershad\xa0M', 'year': '2022', 'journal-title': 'N Acetylcysteine.'}, {'key': 'key-A129817REF20-20', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/CS20180157'}, { 'key': 'key-A129817REF21-21', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879-021-06509-6'}, { 'key': 'key-A129817REF22-22', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13063-021-05242-4'}, { 'key': 'key-A129817REF23-23', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa1443'}, { 'key': 'key-A129817REF24-24', 'doi-asserted-by': 'publisher', 'DOI': '10.18203/2320-6012.ijrms20204010'}, { 'key': 'key-A129817REF25-25', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s43440-021-00296-2'}, { 'key': 'key-A129817REF26-26', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/23744235.2021.1945675'}, { 'key': 'key-A129817REF27-27', 'doi-asserted-by': 'publisher', 'DOI': '10.4236/aid.2020.103006'}, { 'key': 'key-A129817REF28-28', 'doi-asserted-by': 'publisher', 'DOI': '10.12688/f1000research.23995.2'}, { 'key': 'key-A129817REF29-29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.clim.2020.108544'}, { 'key': 'key-A129817REF30-30', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/1024907918794559'}], 'container-title': 'Jundishapur Journal of Natural Pharmaceutical Products', 'original-title': [], 'link': [ { 'URL': 'https://brieflands.com/articles/jjnpp-129817.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://brieflands.com/articles/jjnpp-129817.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 3, 19]], 'date-time': '2023-03-19T15:19:25Z', 'timestamp': 1679239165000}, 'score': 1, 'resource': {'primary': {'URL': 'https://brieflands.com/articles/jjnpp-129817.html'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 13]]}, 'references-count': 30, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 1, 13]]}}, 'alternative-id': ['c87f63dd101c5cbe2eb1093e8588b2b5ec847caf'], 'URL': 'http://dx.doi.org/10.5812/jjnpp-129817', 'relation': {}, 'ISSN': ['1735-7780', '2228-7876'], 'subject': ['General Pharmacology, Toxicology and Pharmaceutics'], 'container-title-short': 'Jundishapur J Nat Pharm Prod', 'published': {'date-parts': [[2023, 1, 13]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit